Department of Internal Medicine III, University of Ulm, Albert Einstein Allee 23, Ulm, Germany.
Blood. 2011 Feb 3;117(5):1622-32. doi: 10.1182/blood-2010-08-300160. Epub 2010 Nov 29.
The DNA damage pathway plays a central role in chemoresistance in chronic lymphocytic leukemia (CLL), as indicated by the prognostic impact of TP53 and ATM loss/mutations. We investigated the function of the p53 axis in primary CLL samples by studying p53 and p21 responses to irradiation by FACS and RT-PCR. We observed a distinct response pattern for most cases with a 17p deletion (n = 16) or a sole TP53 mutation (n = 8), but not all cases with a p53 aberration were detected based on a number of different assays used. Samples with a small clone with a TP53 mutation remained undetected in all assays. Only 1 of 123 cases showed high expression of p53, which is suggestive of p53 aberration without proof of mutation of TP53. Samples with an 11q deletion showed a heterogeneous response, with only 13 of 30 showing an abnormal response based on cutoff. Nevertheless, the overall induction of p53 and p21 was impaired, suggesting a gene-dosage effect for ATM in the 11q-deleted samples. The detectability of p53 defects is influenced by clonal heterogeneity and sample purity. Functional assays of p53 defects will detect a small number of cases not detectable by FISH or TP53 mutational analysis. The clinical utility of functional p53 testing will need to be derived from clinical trials.
DNA 损伤通路在慢性淋巴细胞白血病(CLL)的化疗耐药中起着核心作用,这一点可以从 TP53 和 ATM 缺失/突变的预后影响中得到证明。我们通过研究 FACS 和 RT-PCR 检测照射后 p53 和 p21 的反应,研究了 p53 轴在原发性 CLL 样本中的功能。我们观察到大多数 17p 缺失(n=16)或仅有 TP53 突变(n=8)的病例存在明显的反应模式,但并非所有存在 p53 异常的病例都能通过使用的多种不同检测方法检测到。基于使用的许多不同的检测方法,检测到了具有 TP53 突变的小克隆的样本,但仍有一些未被检测到。在所有检测方法中,只有 1/123 例显示出高表达的 p53,这表明存在 p53 异常,而无需证明 TP53 突变。11q 缺失的样本表现出异质性的反应,只有 30 例中的 13 例基于截止值显示异常反应。然而,总体上 p53 和 p21 的诱导受到损害,这表明在 11q 缺失的样本中,ATM 的基因剂量效应。p53 缺陷的检测能力受到克隆异质性和样本纯度的影响。p53 缺陷的功能检测将检测到一些通过 FISH 或 TP53 突变分析无法检测到的病例。功能 p53 检测的临床实用性将需要从临床试验中得出。